IHE ETF Analysis: U.S. Pharmaceuticals | NYSE
Health | NYSE, USA | Market Cap: 1.438m USD | 12M Return: 50% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 23.4M
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
The iShares U.S. Pharmaceuticals ETF (IHE) tracks an index composed of U.S. pharmaceutical companies, including manufacturers of prescription drugs, over-the-counter medications, and vaccines. As a passively managed fund, it invests at least 80% of its assets in the component securities of its underlying index, with the remaining portion potentially allocated to futures, options, swap contracts, and cash equivalents. The fund is classified as non-diversified, meaning it may hold a more concentrated portfolio than diversified ETFs.
The pharmaceutical sector is characterized by high research and development costs, long product development cycles, and significant reliance on patent protection and regulatory approvals from bodies such as the U.S. Food and Drug Administration (FDA). Industry performance is often influenced by drug pricing dynamics, healthcare policy decisions, and the timing of patent expirations, which can open markets to generic competition.
- IRA Medicare drug price negotiations pressure pharma margins
- GLP-1 obesity drug sales surge lifts top holdings
- Patent cliff risks threaten blockbuster drug revenues
As of July 24, 2026, the stock is trading at USD 101.99 with a total of 1,440,830 shares traded. Over the past week, the price has changed by +1.86%, over one month by +8.36%, over three months by +17.76% and over the past year by +49.97%.
Current recommended Stop Loss: 99.80 (which is 2.1% or 1.3 ATR below the current price).
U.S. Pharmaceuticals has no consensus analysts rating.